[ad_1]
A brand new firm has emerged that’s focusing on the objective of bioprinting kidney tissue (and ultimately kidney organs) for implantation. Trestle Biotherapeutics, a non-public firm primarily based in San Diego, has entered right into a license settlement with Harvard College. Below the settlement, Trestle will commercialize a collection of stem cell- and 3D biofabrication-based regenerative medication applied sciences developed by Professor Jennifer Lewis Lab at Harvard’s Wyss Institute for Biologically Impressed Engineering, Harvard John A. Paulson College of Engineering and Utilized Sciences (SEAS), and Brigham and Ladies’s Hospital.
The core of the know-how being licensed to Trestle was developed by a multi-disciplinary analysis workforce within the laboratories of Jennifer Lewis, Sc.D. and Ryuji Morizane, M.D., Ph.D. Lewis, whom we had the respect to fulfill in particular person when visiting Harvard in 2017, is a Wyss Core School member, leads the Wyss Institute’s 3D Organ Engineering Initiative, is the Hansjörg Wyss Professor of Biologically Impressed Engineering at Harvard SEAS, and is a Principal School member of the Harvard Stem Cell Institute. Dr. Morizane is a Principal Investigator at Massachusetts Basic Hospital, an Assistant Professor at Harvard Medical College, an Affiliated School member at Harvard Stem Cell Institute, and a Visiting Scholar on the Wyss Institute. Drs. Lewis and Morizane are each members of Trestle’s scientific advisory board.
Organovo, additionally primarily based in California, was one of many first firms to aim the event of kidney tissue by way of bioprinting nevertheless the know-how had confirmed too immature on the time. Lots has occurred since and Jennifer Lewis’ Lab has carried out among the most superior analysis into bioprinted implantable tissues and vascularity. Amongst different successes, the Lewis Lab created a multi-material, bioprinting platform that permits the fabrication of 3D tissues composed of a number of cell varieties, engineered extracellular matrices, and vasculature. These vascularized tissues are at the moment beneath improvement for elementary research associated to drug screening, illness modeling, and tissue restore and regeneration.
“Sufferers residing with kidney failure have had the identical two standard-of-care remedy choices for greater than 60 years. We’re actually excited to embark on the bold mission of fixing that and constructing upon the work of the Lewis and Morizane labs in direction of making this a actuality for these sufferers,” mentioned Ben Shepherd, Ph.D., Co-Founder and CEO of Trestle.
The know-how to be commercialized by Trestle not solely allows the speedy fabrication of vascularized kidney tissue at scale for regenerative medication options but in addition paves the best way for rising tissue maturation and vascular improvement inside stem cell-derived organoids in response to fluid move. These are important parts of constructing massive, useful tissues which can at some point be used to complement, and even substitute, renal perform in kidney failure sufferers.
“Trestle was based with the assumption that recreating patterns and processes present in nature is vital to constructing useful tissues. The following period of cell therapies and regenerative medication, significantly for addressing illnesses arising from advanced organs such because the kidney, will depend on the combination of a number of advancing disciplines. Developmental biology, stem cell biology, and 3D biofabrication are core parts of this strategy. We look ahead to integrating the progressive work from Drs. Lewis and Morizane into the platform we’re constructing,” mentioned Alice Chen, Ph.D., Co-Founder and CSO Trestle.
[ad_2]
